

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived human Mer protein			
	Human Mer (Arg26-Ala499) Accession # AAB60430.1	IEGRMD	Human IgG ₁ (Pro100-Lys330)	Avi-tag
	N-terminus		C-terminus	
N-terminal Sequence Analysis	Arg26			
Structure / Form	Disulfide-linked homodimer Biotinylated via Avi-tag			
Predicted Molecular Mass	78 kDa (monomer)			

SPECIFICATIONS


SDS-PAGE	113 - 133 kDa, under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA. When Biotinylated Recombinant Human Mer Fc Chimera Avi-tag protein is immobilized onto a Streptavidin Coated Plate (Catalog # CP004), Recombinant Human GAS6 (Catalog # 885-GSB) binds with an ED ₅₀ of 0.300-1.80 µg/mL. The biotin to protein ratio is greater than 0.7 as determined by the HABA assay.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.


DATA

Binding Activity



Biotinylated Recombinant Human Mer Fc Chimera Avi-tag Protein Binding Activity. When Biotinylated Recombinant Human Mer Fc Chimera Avi-tag Protein (Catalog # AVI891) is immobilized onto a Streptavidin Coated Plate (Catalog # CP004), Recombinant Human Gas6 (Catalog # 885-GSB) binds with an ED₅₀ of 0.300-1.80 µg/mL.

SDS-PAGE



Biotinylated Recombinant Human Mer Fc Chimera Avi-tag Protein SDS-PAGE. 2 µg/lane of Biotinylated Recombinant Human Mer Fc Chimera Avi-tag Protein (Catalog # AVI891) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 113-133 kDa and 226-266 kDa, respectively.

BACKGROUND

Tyrosine-protein Kinase Mer, also known as c-Mer and MerTK, is a member of the receptor tyrosine kinase subfamily TAM (Tyro3, Axl, and Mer). Mature human Mer consists of 485 aa extracellular domain, 21 aa transmembrane domain, and 473 aa cytoplasmic domain. Within the extracellular domain, human Mer shares 77.2% and 76.6% homology with mouse and rat Mer, respectively. Similar to Axl and Tyro3, the extracellular domain of Mer contains two Ig-like motifs and two fibronectin type III motifs. Mer is not expressed in normal B- and T-cells but expressed in neoplastic B- and T-cell lines (1-2). It is also show higher expression in immunosuppressive M2-like macrophages (3). Mer is known to bind Gas6, Protein S, Tubby, Tubby-like protein 1 (Tulp1), and Galectin-3 (4-7). Upon binding ligands via the Ig-like motif, Mer is dimerized to trans-autophosphorylate the kinase domain to induce downstream signaling. It has been shown that Mer signaling in macrophages induces M2 polarization, which promote tumor growth, metastasis and evasion of anti-tumor immunity in tumor microenvironment (8). Inhibition of Mer, especially on leukocytes and macrophages, is an effective anti-cancer therapy (9). Our Avi-tag Biotinylated Mer Fc Chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References:

1. Graham, D.K. *et al.* (1994) *Cell Growth Differ.* **5**:647.
2. Graham, D.K. *et al.* (2006) *Clin. Cancer Res.* **12**:2662.
3. Shibata, T. *et al.* (2014) *J. Immunol.* **192**:3569.
4. Nagata, K. *et al.* (1996) *J. Biol. Chem.* **271**:30022.
5. Uehara, H. *et al.* (2008) *J. Immunol.* **180**:2522.
6. Caberoy, N.B. *et al.* (2010) *EMBO J.* **29**:3898.
7. Caberoy, N.B. *et al.* (2012) *J. Cell Physiol.* **227**:401.
8. Kim, S.Y. *et al.* (2016) *Sci. Rep.* **6**:29673.
9. Cummings, C.T. *et al.* (2013) *Clin. Cancer Res.* **19**:5275.